Benitec Biopharma AI Stock Analysis
Want to see BNTC full AI Analyst Report?
Benitec Biopharma (BNTC) AI Stock Analysis
Benitec Biopharma
(NASDAQ:BNTC)
The score is held down primarily by weak financial performance (no revenue, sizable ongoing losses, and continued negative cash flow), with technicals also indicating a broader downtrend. Offsetting factors include a very low-debt balance sheet with meaningful cash and positive corporate events tied to encouraging BB-301 clinical results and continued regulatory progress.
Benitec Biopharma (BNTC) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $284.35M
- Dividend Yield
- ―
- Average Volume (3M)
- 177.45K
- Price to Earnings (P/E)
- -7.8
- Beta (1Y)
- 0.92
- Revenue Growth
- ―
- EPS Growth
- -12.64%
- Country
- US
- Employees
- 24
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Benitec Biopharma Business Overview & Revenue Model
Company Description
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. Its Silence and Replace, a DNA-directedRNA interference platform combines RNA interference with gene therapy to create medicines th...
Benitec Biopharma Financial Statement Overview
Summary
Development-stage profile with $0 revenue and large recurring losses (TTM net loss ~-$49.5M; EBIT ~-$55.9M) keeps fundamentals weak. Offsetting this, the balance sheet is a key strength with minimal debt (~$0.64M vs. equity ~$169.6M) and cash burn has moderated versus 2025, though operating cash flow and free cash flow remain negative (~-$17.3M TTM).
Income Statement
9Very NegativeBalance Sheet
66PositiveCash Flow
22Negative| Breakdown | TTM | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 0 | 0 | 75.00K | 73.00K |
| Gross Profit | -363.00K | -481.00K | -396.00K | 0 | 75.00K | 64.00K |
| EBITDA | -53.93M | -50.71M | -41.37M | -21.66M | -18.70M | -17.78M |
| Net Income | -49.51M | -45.55M | -37.92M | -21.75M | -19.56M | -18.21M |
Balance Sheet | ||||||
| Total Assets | 179.10M | 182.62M | 99.59M | 52.21M | 4.46M | 5.97M |
| Cash, Cash Equivalents and Short-Term Investments | 176.37M | 179.97M | 97.74M | 50.87M | 2.48M | 4.06M |
| Total Debt | 642.00K | 762.00K | 849.00K | 284.00K | 559.00K | 811.00K |
| Total Liabilities | 9.45M | 5.61M | 2.30M | 4.96M | 4.26M | 3.09M |
| Stockholders Equity | 169.65M | 177.01M | 97.30M | 47.25M | 202.00K | 2.88M |
Cash Flow | ||||||
| Free Cash Flow | -17.36M | -16.62M | -23.61M | -19.58M | -18.01M | -15.91M |
| Operating Cash Flow | -17.25M | -16.52M | -23.59M | -19.40M | -18.01M | -15.90M |
| Investing Cash Flow | -106.04K | -105.00K | -18.00K | -179.00K | -1,000 | -13.00K |
| Financing Cash Flow | 102.83M | 98.98M | 70.48M | 68.03M | 16.02M | 0 |
Benitec Biopharma Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BNTC, the sentiment is Negative. The current price of 8.15 is below the 20-day moving average (MA) of 8.91, below the 50-day MA of 9.59, and below the 200-day MA of 11.37, indicating a bearish trend. The MACD of -0.10 indicates Negative momentum. The RSI at 43.35 is Neutral, neither overbought nor oversold. The STOCH value of 27.55 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BNTC.
Benitec Biopharma Risk Analysis
Benitec Biopharma disclosed 67 risk factors in its most recent earnings report. Benitec Biopharma reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
1 New RiskBenitec Biopharma Peers Comparison
Overall Rating
PEPG59Neutral
KRRO55Neutral
DTIL54Neutral
BNTC48Neutral
EDIT47Neutral
PRQR40Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 59Neutral | $268.73M | -3.13 | -58.18% | ― | ― | 62.59% | |
| 55Neutral | $169.10M | -1.35 | -117.05% | ― | -82.47% | 3.73% | |
| 54Neutral | $196.95M | -5.71 | -58.09% | ― | 6353.01% | 84.80% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 48Neutral | $294.37M | -7.82 | -27.60% | ― | ― | -12.64% | |
| 47Neutral | $281.67M | -2.97 | -130.43% | ― | 7.43% | 74.00% | |
| 40Underperform | $162.29M | -2.76 | -70.45% | ― | 19.49% | -4.53% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| BNTC | Benitec Biopharma | 8.15 | -4.95 | -37.79% | |
| PRQR | ProQR Therapeutics BV | 1.15 | -0.88 | -43.35% | |
| EDIT | Editas Medicine Inc. | 1.82 | -0.70 | -27.58% | |
| DTIL | Precision Biosciences | 7.05 | 2.23 | 46.27% | |
| KRRO | Korro Bio, Inc. | 12.32 | 5.91 | 92.20% | |
| PEPG | PepGen Inc. | 3.88 | -1.65 | -29.84% |
Benitec Biopharma Corporate Events
Benitec Biopharma Reports Fiscal First-Quarter Results and Clinical Progress
PositiveOn Nov. 13, 2026, Benitec reported first-quarter fiscal 2027 results and clinical updates for BB-301, its investigational treatment for Oculopharyngeal Muscular Dystrophy-related dysphagia. Interim results presented on Oct. 28 showed a 100% responder...
Benitec Biopharma reports positive BB-301 trial results
PositiveOn October 28, 2026, Benitec Biopharma reported positive interim results from its ongoing Phase 1b/2a first-in-human trial of BB-301 in patients with Oculopharyngeal Muscular Dystrophy-related dysphagia. Across both low- and high-dose cohorts, all ni...
Benitec advances BB-301 gene therapy after FDA feedback
PositiveOn October 5, 2026, Benitec Biopharma reported that the U.S. Food and Drug Administration provided formal feedback following a Type C meeting held in the third quarter of 2026 regarding the pivotal study of BB-301, its investigational gene therapy fo...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 14, 2026
